Drugs.com - FDA MedWatch Alerts

FDA Requires Guillain-Barré Syndrome (GBS) Warning in the Prescribing Information for RSV Vaccines Abrysvo and Arexvy

Audience: Patient, Health Care Professional, Pharmacy, Immunology, Pulmonology ISSUE: FDA has required and approved safety labeling changes to the Prescribing Information for Abrysvo (Respiratory Syncytial Virus Vaccine) manufactured by Pfizer Inc...

Feb 9, 2025 - 21:44
 0
FDA Requires Guillain-Barré Syndrome (GBS) Warning in the Prescribing Information for RSV Vaccines Abrysvo and Arexvy
Audience: Patient, Health Care Professional, Pharmacy, Immunology, Pulmonology ISSUE: FDA has required and approved safety labeling changes to the Prescribing Information for Abrysvo (Respiratory Syncytial Virus Vaccine) manufactured by Pfizer Inc...
Read More

Tags:

Previous Article

FDA Warns Health Care Professionals Not to Use Epinephrine Nasal Solutions from ...

Next Article

Astellas Issues Recall of One Lot of Prograf 0.5 mg and One Lot of Astagraf XL 0...

Related Posts

Boulla LLC Issues Voluntary Nationwide Recall of ZoomMax and ZapMax Capsules Due to the Presence of Undeclared Sildenafil and Diclofenac

Boulla LLC Issues Voluntary Nationwide Recall of ZoomMa...

Feb 9, 2025  0

CAPS Issues Recall of Phenylephrine 40 mg Added to 0.9% Sodium Chloride 250 mL in 250 mL Excel Bags Due to Visible Black Particulate Matter in a Single-Sealed Vial

CAPS Issues Recall of Phenylephrine 40 mg Added to 0.9%...

Feb 26, 2025  0

Veata LLC Issues Voluntary Nationwide Recall of Endurance Pro Capsules Due to the Potential Presence of Undeclared Sildenafil

Veata LLC Issues Voluntary Nationwide Recall of Enduran...

Feb 9, 2025  0